IMGN - ImmunoGen Inc Stock Price, Fair Value and News

31.23USD Market Closed

Market Summary

USD31.23

Market Closed

IMGN Stock Price

View Fullscreen

IMGN RSI Chart

IMGN Valuation

Market Cap

8.3B

Price/Earnings (Trailing)

-113.1

Price/Sales (Trailing)

28.91

EV/EBITDA

-35.08

Price/Free Cashflow

-41.62

IMGN Price/Sales (Trailing)

IMGN Profitability

EBT Margin

-38.01%

Return on Equity

-13.09%

Return on Assets

-8.94%

Free Cashflow Yield

-2.4%

IMGN Fundamentals

IMGN Revenue

Revenue (TTM)

287.6M

IMGN Earnings

Earnings (TTM)

-73.5M

Breaking Down IMGN Revenue

Last 7 days

6.7%

Last 30 days

5.3%

Last 90 days

111.6%

Trailing 12 Months

570.2%

How does IMGN drawdown profile look like?

IMGN Financial Health

Current Ratio

5.7

Debt/Equity

Debt/Cashflow

-94.91

IMGN Investor Care

Shares Dilution (1Y)

20.62%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	120.6M	189.6M	287.6M	0
2022	92.2M	89.4M	95.6M	108.8M
2021	134.7M	136.6M	127.7M	69.9M
2020	87.0M	86.5M	91.4M	132.3M
2019	42.2M	48.5M	50.8M	82.3M
2018	106.8M	77.0M	79.5M	53.4M
2017	57.4M	89.0M	89.8M	115.4M
2016	65.2M	60.0M	52.8M	48.6M
2015	78.7M	85.5M	87.2M	56.9M
2014	58.0M	59.9M	55.9M	74.1M
2013	34.7M	35.5M	48.7M	76.1M
2012	19.9M	16.4M	17.9M	12.9M
2011	18.0M	19.3M	18.4M	21.9M
2010	0	13.9M	15.3M	16.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About ImmunoGen Inc

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Mark Joseph Enyedy
WEBSITE	immunogen.com
INDUSTRY	Biotechnology
EMPLOYEES	277

ImmunoGen Inc Frequently Asked Questions

What is the ticker symbol for ImmunoGen Inc? What does IMGN stand for in stocks?

IMGN is the stock ticker symbol of ImmunoGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ImmunoGen Inc (IMGN)?

As of Tue Feb 13 2024, market cap of ImmunoGen Inc is 8.32 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMGN stock?

You can check IMGN's fair value in chart for subscribers.

Is ImmunoGen Inc a good stock to buy?

The fair value guage provides a quick view whether IMGN is over valued or under valued. Whether ImmunoGen Inc is cheap or expensive depends on the assumptions which impact ImmunoGen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMGN.

What is ImmunoGen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 13 2024, IMGN's PE ratio (Price to Earnings) is -113.1 and Price to Sales (PS) ratio is 28.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IMGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ImmunoGen Inc's stock?

In the past 10 years, ImmunoGen Inc has provided 0.077 (multiply by 100 for percentage) rate of return.